When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
SCYX - Scynexis' ibrexafungerp an Orphan Drug in Europe for invasive candidiasis
SCYNEXIS Inc.
Scynexis (NASDAQ:SCYX) announces that the EMA has granted orphan medicinal product designation to ibrexafungerp for the indication of invasive candidiasis (IC). Shares up 2.3% premarket at $6.78. Among the benefits of Orphan Drug status in Europe is a 10-year period of market exclusivity for the indication, protocol assistance, reduced regulatory, if approved. Recently, Scynexis launches late-stage oral ibrexafungerp study in IC.